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the most common autosomal-recessive Mendelian phenotype of amino acid metabolism. We estimated
that globally 0.45 million individuals have PKU, with global prevalence 1:23,930 live births (range 1:4,500
[Italy]–1:125,000 [Japan]). Comparing genotypes and metabolic phenotypes from 16,092 affected subjects
revealed differences in disease severity in 51 countries from 17 world regions, with the global phenotype
distribution of 62% classic PKU, 22% mild PKU, and 16% mild hyperphenylalaninemia. A gradient in
genotype and phenotype distribution exists across Europe, from classic PKU in the east to mild PKU in
the southwest and mild hyperphenylalaninemia in the south. The c.1241A>G (p.Tyr414Cys)-associated
genotype can be traced from Northern to Western Europe, from Sweden via Norway, to Denmark, to the
Netherlands. The frequency of classic PKU increases from Europe (56%) via Middle East (71%) to Aus-
tralia (80%). Of 758 PAH variants, c.1222C>T (p.Arg408Trp) (22.2%), c.1066−11G>A (IVS10−11G>A)
(6.4%), and c.782G>A (p.Arg261Gln) (5.5%) were most common and responsible for two prevalent
genotypes: p.[Arg408Trp];[Arg408Trp] (11.4%) and c.[1066−11G>A];[1066−11G>A] (2.6%). Most geno-
types (73%) were compound heterozygous, 27% were homozygous, and 55% of 3,659 different genotypes
occurred in only a single individual. PAH variants were scored using an allelic phenotype value and
correlated with pre-treatment blood phenylalanine concentrations (n = 6,115) and tetrahydrobiopterin
loading test results (n = 4,381), enabling prediction of both a genotype-based phenotype (88%) and
tetrahydrobiopterin responsiveness (83%). This study shows that large genotype databases enable accu-
rate phenotype prediction, allowing appropriate targeting of therapies to optimize clinical outcome.
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Phenylketonuria (PKU), caused by variants in the phenylalanine hydroxylase (PAH) gene, is 
the most common autosomal recessive Mendelian phenotype of amino acid metabolism. We 
estimated that globally 0.45 million individuals have PKU, with global prevalence 1:23,930 
live births (range 1:4,500 [Italy] - 1:125,000 [Japan]). Comparing genotypes and metabolic 
phenotypes from 16,092 patients revealed differences in diseases severity in 51 countries from 
17 world regions, with the global phenotype distribution of 62% classic PKU, 22% mild PKU 
and 16% mild hyperphenylalaninemia. A gradient in genotype and phenotype distribution 
exists across Europe, from classic PKU in the east, to mild PKU in the southwest and mild 
hyperphenylalaninemia in the south. The c.1241A>G (p.Tyr414Cys)-associated genotype can 
be traced from Northern to Western Europe, from Sweden via Norway, Denmark to the 
Netherlands. The frequency of classic PKU increases from Europe (56%) via Middle East 
(71%) to Australia (80%).  Of 758 PAH variants, c.1222C>T (p.Arg408Trp) (22.2%), c.1066-
11G>A (IVS10-11G>A) (6.4%) and c.782G>A (p.Arg261Gln) (5.5%) were most common 
and responsible for two prevalent genotypes: p.[Arg408Trp];[Arg408Trp] (11.4%) and 
c.[1066-11G>A];[1066-11G>A] (2.6%). Most genotypes (73%) were compound 
heterozygous, 27% were homozygous and 55% of 3,659 different genotypes occurred in only 
a single patient. PAH variants were scored using an allelic phenotype value and correlated 
with pre-treatment blood phenylalanine concentrations (n=6,115) and tetrahydrobiopterin 
loading test results (n=4,381), enabling prediction of both a genotype-based phenotype (88%) 
and tetrahydrobiopterin responsiveness (83%). This study shows that large genotype 
databases enable accurate phenotype prediction, allowing appropriate targeting of therapies to 
optimize clinical outcome. 
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Introduction  
Phenylketonuria (PKU; MIM 261600) is the most frequent inborn error of the amino acid 
metabolism. More than 1,180 biallelic variants in the phenylalanine hydroxylase (PAH) gene 
located on chromosome 12q22-24.1 have been identified.1 These autosomal recessive 
inherited variants lead to deficiency in the PAH enzyme, which hydroxylates phenylalanine to 
tyrosine, with the help of a cofactor (tetrahydrobiopterin; BH4), molecular oxygen, and non-
heme iron.2  
The metabolic picture is highly heterogenous as it depends on the degree of residual PAH 
activity and blood phenylalanine (Phe) concentrations. Lower residual enzyme activity 
usually results in higher blood Phe concentrations and a more severe clinical phenotype if left 
untreated.3  
The severity of PKU is defined by daily Phe tolerance.4 Standard classification is according to 
the pre-treatment blood Phe concentration and daily dietary Phe tolerance, ranging from the 
severe classical PKU (cPKU) with pre-treatment blood Phe concentrations of >1,200 µmol/L, 
to mild PKU (mPKU) with pre-treatment blood Phe concentrations of 600–1,200 µmol/L and 
mild hyperphenylalaninemia (MHP) with pre-treatment Phe blood concentrations of 120–600 
μmol/L.1; 5 
Untreated PKU generally results in global developmental delay or severe irreversible 
intellectual disability, as well as growth failure, hypopigmentation, motor deficits, ataxia, and 
seizures.1 The population of PKU patients is heterogeneous in terms of treatment history and 
diet compliance.5; 6 Early diagnosis and treatment with a low-Phe diet has enabled an almost 
normal life for the majority of PKU patients.7 Pharmacological treatment with BH4 
(sapropterin) and enzyme substitution therapy with Phe ammonia lyase (PAL) provide 
alternative treatment options for some patients.8   
PKU is one of the most frequent inherited disorders in Caucasians, with an incidence of 
roughly 1:10,000 live births in the USA,9 although the prevalence of PKU varies significantly 
among ethnicities and geographic regions worldwide. In Europe, the incidence of PKU ranges 
from 1: 850 in the Karachay-Cherkess Republic (Russia)10 to only 1:112,000 live births in 
Finland.11 PKU occurs less often in Japan, with an incidences of 1:125,000.12  
A large number of PAH variants give rise to a wide scale of residual PAH enzyme activities 
that correspond to different PKU phenotypes.13; 14 Associations between genotypes and in 
vitro residual PAH activity have been documented for many PAH variants.3 Therefore, the 
molecular genetics of PKU and genotype-based phenotype prediction may be clinically 
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useful, particularly where treatment recommendations are unclear (e.g. due to borderline 
blood phenylalanine concentrations) or for genetic counseling of patients’ families. 
The major goal of this study was the analysis of a large database of PKU phenotype and 
genotype to elucidate the current distribution of PKU worldwide and to create an overview of 
the severity of PAH variants, genotypes and the resulting phenotypes, in various geographic 
regions and respective countries. Furthermore, this work improves the accuracy of genotypic 
phenotype prediction by the use of the allelic phenotype value (APV) value and the genotypic 
BH4 responsiveness prediction. 
Subjects and methods 
Literature search 
An electronic search using the databases MEDLINE (via Pub Med), the Cochrane library and 
Web of Science was carried out to compare articles that were published between January 
1980 and October 2019, covering the epidemiology and genetics of PKU in different world 
regions. Key words included Phenylketonuria[MeSH Terms] OR "phenylalanine 
hydroxylase/deficiency"[MeSH Terms] OR hyperphenylalaninaemia[Title/Abstract] OR 
hyperphenylalaninemia[Title/Abstract] OR PAH deficiency[Title/Abstract] OR phenylalanine 
hydroxylase deficiency[Title/Abstract] OR phenylketonuri*[Title/Abstract] OR 
pku[Title/Abstract]) AND ( "1980/01/01"[PDat] : "2019/12/31"[PDat] ) AND 
Humans[Mesh] Filters: Publication date from 1980/01/01 to 2019/12/31; Humans. 
This literature search yielded 5,459 records without duplicates, of which 1,118 papers with an 
appropriate title and abstract were assessed. The final number of relevant records was 256. 
(Figure S1) 
Databases 
The PAH locus-specific database PAHvdb, ClinVar, HGMD and LOVD databases were 
searched for variants. PAHvdb is linked to the genotype-phenotype BIOPKU database and 
was used for analyses. The RefSeq accession number for the PAH is ENSG00000171759; 
GeneBank: NM_000277.1. All variants were tested using Mutalyzer 2.0 and follow the 
HGVS guidelines.   
The BIOPKU database encompasses information about more than 16,900 PKU patients from 
51 countries, providing information on patient genotypes, corresponding metabolic 
phenotypes, BH4 responsiveness (where reported) and highest blood Phe concentrations 
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before starting treatment (where reported). Individual information was collected from the 
published literature or anonymized records submitted online. Phenotype information was 
unknown for 690 patients. Data in the database are anonymized and cannot be traced back to 
the families. Purpose of the database was to provide an online search tool for reported PAH 
variants or genotypes, with an output summarizing the number of records, phenotype 
distribution, BH4 responsiveness and regional and counties distribution. As mentioned above, 
BIOPKU is linked with the PAHvdb, thus providing additional information incl. allelic 
phenotype values (APV). Data submissions and procedures followed were in accordance with 
the ethical standards and were approved by local institutional review boards where applicable. 
Table 1 shows the information included in the database. 
Definition of phenotypes 
Since not all countries use the same nomenclature for the severity of PAH deficiency, in this 
study the following 3 metabolic phenotype groups were used: classical PKU (cPKU; pre-
treatment blood Phe >1,200 µmol/L); mild PKU (mPKU; pre-treatment blood Phe 600–1,200 
µmol/L) and mild hyperphenylalaninemia (MHP; pre-treatment blood Phe 120–600). Patients 
with a moderate PKU (pre-treatment blood Phe 900–1,200 µmol/L) were included in the 
mPKU group and MHP included MHP-no treatment (blood Phe 120–360 µmol/L) and MHP-
gray zone (360–600 µmol/L) categories.5-7  Any classifications, not fitting into one of the 
above groups (due to different country-specific classifications), were reassigned on the basis 
of reported pre-treatment blood Phe concentrations. However, neither the method used for 
blood Phe quantification nor the age at measurement were reported.  
Definition of the allelic (APV) and genotypic phenotype value (GPV) 
APV is a value defining the association of a variant with the corresponding metabolic 
phenotype, thus defining its severity. APV was calculated for variants occurring in a 
functionally hemizygous constellation (i.e. in a combination with an inactive null allele) in at 
least 5 patients.15 APVs range between 0 and 10, with following classifying definitions cPKU 
(APV = 0-2.7), mPKU (APV = 2.8-6.6) and MHP (APVs 6.7-10).15  
The genotypic phenotype value (GPV) was calculated from the APVs of both alleles and was 
assigned to a higher APV (APVmax). This calculation was based on the fact that the milder 
variant (with a higher APV) is always dominant over the severe one.15; 16 Possible effects of 
interallelic complementation and epigenetic factors, which may influence the phenotype17; 18, 
were not considered in this study. 
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Definition of BH4 responsiveness 
BH4 responsiveness was defined as a ≥30% reduction of blood Phe concentrations within 24-
48 hours after the administration of BH4 (20mg/kg body weight)
19; 20. The protocols for the 
BH4 challenge were different in different centers (i.e. 24h, 48h, 1 day, 1 week, etc.) and for 
this reason BH4 responsiveness was simply reported as “yes” or “no”. A linear discriminant 
analysis was applied to predict BH4 responsiveness based on the APV for untested patients.  
Statistical analysis 
Statistical analysis was performed using R, an open source software and flexible 
programming language used for the statistical data analysis as well as graphic creations 
(https://www.r-project.org/). A total of 16,196 records with a complete genotype information 
(variant 1 and 2 known) were analyzed. Two linear discriminant analyses (LDA) were 
computed: first LDA was computed to predict the clinical phenotype (cPKU, mPKU and 
MHPA) from individual's GPV, the second LDA was computed to predicted BH4 
responsiveness by GPV value from untested individuals in BIOPKU. 
 
Results 
Prevalence of PKU 
Based on the literature search and reports from national screening centers, the prevalence of 
PKU was estimated for 64 countries. For parts of Africa, Asia, South America and Caribbean 
there was no information. The estimated total number of PKU patients (all phenotypes) from 
those 64 countries in 2018 was 360,466. For the remaining 257 countries we were unable to 
find credible PKU prevalence sources; we used the average regional prevalence of 64 
countries, multiplied by their populations, resulting in an additional 94,114 PKU patients 
(total about 0.45 million PKU patients). The global PKU prevalence was estimated to be 1: 
23,930 newborns (Figure 1, Table S1). 
The PKU prevalence was highest in European and certain Middle Eastern populations. Italy 
(1:4,000) and Ireland (1:4,545) had even higher prevalence than Iran and Jordan (both 1: 
5,000) or Turkey (1:6,667). However, Saudi Arabia (1:14,245), Iraq (1:14,286) or United 
Arab Emirates (1:14,493) had lower PKU prevalence. 
PKU prevalence was also high in Central European countries, e.g. Germany (1:5,360), 
Czechia (1:5,521), Austria (1:5,764) and Slovakia (1:5,753). Slovenia (1:7,143) and Poland 
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(1:8,309) had similar rates to Eastern Europe, e.g. Estonia (1:7,143), Russia (1: 7,714) Belarus 
(1:7,692), and Croatia (1:8,333).  
PKU occurred slightly less frequently in Western Europe, e.g. in France (1:9,091), United 
Kingdom (1:10,000), Belgium (1:11,000) or the Netherlands (11,546), and in Southern 
Europe, e.g. Spain (1:10,115) or Portugal (1:12,500).   
Northern Europe showed the lowest PKU rates in Europe, e.g. Norway (1:11,457), Sweden 
(1: 12,681), Denmark (1: 13,434), or only 1:112,000 in Finland. 
PKU occurred more frequently In Canada (1:15,000) than in the United States of America 
(1:25,000) or in Latin American countries, e.g., Argentina (1:15,715), Chile (1:19,231), Brazil 
(1:25,000), Mexico (1:27,778) or Peru (1:46,970).  
The lowest PKU prevalence was reported in Asian countries, such as Thailand (1:227,273), 
Japan (1:125,000), Philippines (1:116,006) or Singapore (1:83,333). One exception was China 
where the PKU prevalence was 1:15,924, which was comparable to Europe.  
Descriptive analysis of the phenylalanine hydroxylase gene locus-specific database 
Substitutions were by far the most frequent variant type in the PAHvdb (80.5%), followed by 
deletions (12.9%) and duplications (2.1%). Of all variants, 691 were missense variants 
(58.3%), followed by 165 frameshift variants (13.9%) and 155 splice site (13.1%) variants. 
Nonsense variants (6.9%), synonymous variants (4.9%) and in-frame variants (1.9%) were 
less frequent. Extension, complex and unknown variants, accounted for the remainder. Exon 6 
contained the largest number of variants (14.1%), followed by exon 7 (12.2%) and exon 3 
(9.9%). Most variants (59.2%) were located in the central catalytic domain, 17.5% in the N-
terminal regulatory domain and 5.4% in the C-terminal oligomerization domain of the PAH 
monomer. The remaining variants (17.9%) were either in the intronic or UTR regions. Only 
7.7% of all variants were located in one of the 4 cofactor binding regions (Figure S2). 
The APV was known for 589 of 1,186 variants. Most variants (441) were defined as severe 
null alleles (APV=0), 32 variants as cPKU phenotype, 52 as mPKU and 64 as MHP alleles. 
Metabolic phenotype was predicted, on the basis of the known genotype and corresponding 
GPV from the LDA, in 87.9% of PKU patients. 
Descriptive analysis of the BIOPKU database 
As of October 2019, the BIOPKU database contained anonymized data on more than 16,900 
PKU patients. A total of 16,196 PKU patients with 3,659 different genotypes were analyzed. 
Information on the PKU phenotype was available for 16,902 patients, thus some of them 
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(810) with no genotype information. Maximum pretreatment Phe concentrations were 
reported for only 6,371 patients and the BH4 test information was available for 5,597 patients 
(Table 1). 
Global PKU phenotype and genotype distribution 
Information on the PKU phenotype and genotype was available for 16,092 out of 16,196 
patients (99%). Of these, most had cPKU (9,923; 61.7%), 3,521 (21.9%) had mPKU, and 
2,648 had MHP (16.4%). Information about the phenotype was unavailable for 104 patients 
The comparison of pre-treatment Phe level with the reported phenotype (n=6,369) is 
illustrated in Figure 2A and with the GPVs (n=6,115) in Figure 2B. The interquartile range (n, 
median, 25th–75th percentile) was smallest and lowest for the MHP patient group: 1,283, 320 
µmol/L, 242–432 µmol/L, and was larger for mPKU and cPKU (1,487, 793 µmol/L, 660–793 
µmol/L, and 3,599, 1,550 µmol/L, 1,270–1936 µmol/L, respectively).  
A total of 758 different PAH variants were identified in this study. The three most prevalent 
variants were c.1222C>T (p.Arg408Trp), with an allele frequency (AF) = 22.2%, c.1066-
11G>A (IVS10-11G>A; AF=6.4%) and c.782G>A (p.Arg261Gln; AF 5.5%). Figure 4 shows 
the most frequent phenotype-specific variants. A full list of PAH variants is shown in Table 
S2. 
Of all patients, 11,810 (72.9%) were compound heterozygotes and 4,386 (27.1%) were 
homozygotes. Of 3,659 genotypes, 3,446 (94.2%) were compound heterozygotes and 213 
(5.8%) homozygotes. The three most prevalent genotypes were: p.[Arg408Trp];[Arg408Trp] 
with a genotype frequency (GF) =11.4%, followed by c.[1066-11G>A];[1066-11G>A] 
(GF=2.6%) and c.[1222C>T];[1315+1G>A] (p.[Arg408Trp];IVS12+1G>A) (GF=1.6%). A 
full list of genotypes is shown in Table S3. Strikingly, 54.5% of all genotypes were specific 
for only one patient and were not used for the phenotype prediction. 
BH4 responsiveness 
Information on BH4 responsiveness was available for 5,597 patients. About half were 
classified as BH4 responsive (2,316; 43%). Table S4 shows the distribution of BH4 
responsiveness in different phenotype groups. As expected, milder forms of PKU appeared 
more likely to be BH4 responsive, whereas most patients with cPKU were non-responders.   
Pretreatment blood Phe concentrations (n, median, 25th–75th percentile) were much lower for 
BH4 responsive patients (1,116, 620 µmol/L, 411–853 µmol/L), compared with non-
responders (1,180, 1,361 µmol/L, 1,039–1,719 µmol/L (Figure 2C). The 11,584 patients not 
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tested for BH4 responsiveness were analyzed for potential responsiveness using the GPVs. 
Patients with an GPV>3.8 (n=3,023; 26%) were assigned as potential BH4 responders 
(p<0.001 vs. patients assigned as non-responders [n=8,561; 74%]) (Figure 2D). 
PKU phenotypes and genotypes in world regions 
Overview of global data 
Patient data originated from 51 countries from 17 world regions and a total of 15,357 patients 
from 33 countries with at least 35 reported cases were analyzed (Tables S5 and S6, Figure 
S3). Most cases were reported from Central (18.3%) and Eastern (18.1%) Europe, Eastern 
Asia (13.8%), Western Europe (9.6%) and the Middle East (9.2%). Very few patients were 
reported from the northern and southern parts of Africa.  
cPKU was the most frequent phenotype in all world regions, with high rates reported in 
Australia and eastern Europe (81%), and rates of <50% reported only in Serbia, Argentina, 
Turkey, Netherlands, Sweden, Spain, Italy, Japan, Slovenia, Germany, and Taiwan (Figure 
4A). Of 2,835 patients in Russia, 81% had cPKU, 9.9 % had mPKU and 9.1% had MHP. 
Estonia, representing the Baltic region, reported 93.5% of patients with cPKU. The ratio of 
mPKU:MHP patients was comparable, except for Eastern Asia, North America and South 
America, where mPKU was more common. The phenotype distribution in world regions, as 
well as Genotypic Phenotype Values (GPV) for Europe and other world regions is shown in a 
more granular form in Figure S4.   
Reports from individual regions are summarized in Table 2 and below.  
Europe 
Variant p.Arg408Trp was the most common (AF=63.7%) throughout Europe, followed by 
c.1066-11G>A (AF=11%) and p.Arg261Gln (AF=11%). Eastern Europe had the highest AF 
for p.Arg408Trp (54.6%), mostly with homozygous genotype p.[Arg408Trp];[Arg408Trp] 
(GF=32.7%); findings were similar for Central Europe (AF=44.4% and GF=23.8%). Russia 
contributed the largest number of records. A single variant, p.Arg408Trp (AF=53.7%), was 
dominant in Russia, followed by p.Arg261Gln (AF=5.6%) and c.842C>T (p.Pro281Leu; 
AF=4.1%). The most common genotype was p.[Arg408Trp];[Arg408Trp] (30.6% of 458 
different genotypes). In Southeastern Europe p.Arg408Trp was also the most frequent allele, 
but c.[143T>C];[1222C>T] / p.[Leu48Ser];[Arg408Trp] was the most prevalent genotype 
(GF=10.6%) 
The distribution of patients with p.Arg408Trp on at least one allele (compound heterozygotes 
and homozygotes) decreased from 98% in Estonia to 89% in Poland, 76% in Russia, 69% in 
 11
Slovakia, 65% in Czechia, 40% in Austria, 36% in Germany, 10% in France, 6% in Italy, to 
only 4% in Spain (Table 3, Figure 5). Genotypes with the c.1066-11G>A splice site variant, 
occurred commonly in Armenia (48%), Turkey (32%), Iran (26%), Israel (21%), Spain (20%) 
and Italy (19%) (Table 3, Figure 5). The prevalence of p.Arg261Gln was 10–30% in most 
countries. 
PKU phenotypes were more evenly distributed in Southern Europe (39.5% cPKU, 36.6% 
MHP, 23.9% mPKU), and milder phenotypes were more predominant, e.g. 37% had MHP in 
Italy. This was consistent with a high frequency of variants with a substantial residual PAH 
activity, e.g. c.1208C>T (p.Ala403Val; AF=8.4), c.898G>T (p.Ala300Ser; AF=3.6), 
c.734T>C (p.Val245Ala; AF=2.4) or c.1241A>G (p.Tyr414Cys; AF=2.4). Variants c.1066-
11G>A and p.Arg261Gln, often called the “Mediterranean mutation” accounted for majority 
of mutant alleles, and the most frequent genotype was c.[1066-11G>A];[1066-11G>A] 
(GF=5.2%). In Portugal and Italy c.1066-11G>A and p.Arg261Gln occurred at similar rates 
(AF=16.2% and AF=10.7%, respectively). Variant c.1162G>A (p.Val388Met) was also 
common in Portugal (AF=11.3%) and Spain (AF=6.8%). 
Low rates of cPKU were found in Southwestern Europe (42.7%) and Northern Europe 
(50.5%). In Southeastern Europe, Croatia (68%) and Bulgaria (65%) had a higher prevalence 
of cPKU than Serbia (48%). p.Arg408Trp was the most frequent variant in Croatia 
(AF=31.4%) and Bulgaria (AF=32.4%), but less common in Serbia (AF=14.7%). The 
p.Leu48Ser variant, which was initially identified in Turkey,21 has the highest reported AF 
(31.3%) in Serbia. The most frequent genotypes in other countries locally were 
p.[Leu48Ser];[Leu48Ser] (14.7 %) in Serbia; p.[Leu48Ser];[Arg408Trp] (14.3 %) in Croatia; 
and p.[Arg408Trp];[Arg408Trp] genotype (16.2 %) in Bulgaria.  
In Northern Europe c.1315+1G>A was the most common splice site variant (AF=25%). Most 
patients were compound heterozygous for p.[Arg408Trp];c.[1315+1G>A]. Denmark had the 
highest number of cases of the mild p.Tyr414Cys variant in the in the world and Sweden and 
Norway also a relatively high rate of mPKU (>43%). In Denmark the most frequent variant 
was c.1315+1G>A with an AF= 27.3%, while c.136G>A (p.Gly46Ser) occurred more 
commonly in Sweden and Norway. Variants p.Arg408Gln and c.896T>G (p.Phe299Cys) were 
specific for Norway.  
The p.Arg408Trp variant was also the most frequent variant in all Central European countries, 
except for Switzerland where p.Arg261Gln (AF=15.3%) was more prevalent. Classical PKU 
was particularly frequent in Poland and Slovakia (>70%), but not in Czechia, consistent with 
a higher prevalence of the mild variant, p.Ala403Val. There was a wide spectrum of PKU 
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variants in Germany: of 102 distinct variants, p.Arg408Trp accounted for only 19.3%, and 
other variants such as p.Tyr414Cys (AF=9.7 %) as well as c.1315+1G>A (AF=8.8 %) were 
prominent. Almost half (44%) of patients in Germany had the mPKU phenotype, 32% had 
cPKU and 24% had MHP.  
In France (1,307 patients) 59.1% had cPKU, and there were a total of 229 different variants, 
e.g. c.1066-11G>A (AF=7.4%), p.Arg261Gln (AF=6.5%), p.Arg408Trp (AF=5.5%), 
c.1315+1G>A (AF=4.5%) and c.838G>A (p.Glu280Lys; AF=3.7%). The p.Arg408Trp 
variant was also less common in the Netherlands (AF=2.2%). The predominant genotype in 
Western Europe was p.[Glu280Lys];[Glu280Lys]. 
Latin America 
The most frequent variants here, p.Val388Met (AF= 13.9%), p.Arg261Gln (AF=10.7%) and 
c.1066-11G>A (AF=9.4%), were also prominent mutations in Southern Europe (see above). 
Homozygous p.[Val388Met];[Val388Met] (GF=4.4%) occurred most frequently. Of the three 
relevant South American countries, Brazil had the highest numbers of cPKU (63%), followed 
by Mexico (57%) and Argentina (43%). In comparison to Brazil or Argentina, Mexico’s most 
frequent variant was c.60+5G>T (IVS1+5G>T). 
North America 
The most prevalent variants in North America also resembled those in European populations: 
p.Arg408Trp (18.5%), c.1066-11G>A (7.9%), c.1315+1G>A (6.9%), as did the genotype 
distribution p.[Arg408Trp];[Arg408Trp] (GF=4.0%) 
Middle East 
The predominance of c.1066-11G>A variant (AF=20.1%) and its homozygous genotype 
(GF=15.3%) was evident In Iran, Turkey, Israel and Saudi Arabia. Other frequent variants 
included p.Arg261Gln, c.168+5G>C (IVS2+5G>C), p.Pro281Leu and c.727C>T 
(p.Arg243*).  81% of the Iranian patients had cPKU. In comparison to Iran, Turkey had a 
similar AF for c.1066-11G>A (22.9 %) and p.Arg261Gln (11.8 %), but strongly different 
phenotypes: 42% had cPKU, 35% MHP and 23% mPKU. This may be related to the 
augmented presence of mild variants such as p.Ala300Ser (7.4%) or c.1169A>G 
(p.Glu390Gly; 4.2%). In contrast to other Middle Eastern countries, the most frequent variant 
from Saudi Arabia was c.754C>T (p.Arg252Trp; 27,6%), followed by c.781C>T (p.Arg261*; 
11.2 %) and p.Val388Met (10.4 %); 30% of all patients had a p.Arg252Trp-associated 
genotype, i.e., compound heterozygous or homozygous (Table 3).  
Asia 
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Most reported cases from Asia came from the east, with the most prevalent being the 
missense variant c.728G>A (p.Arg243Gln; AF= 21.8%), followed by c.611>G (9.8%) and 
c.721C>T (p.Arg241Cys; 8.7%). The most frequent genotype was homozygous 
p.[Arg243Gln],[Arg243Gln] (GF=5.6%).  
In China, 62% of patients (n=2008) had a cPKU, 28% mPKU and 10% a MHP phenotype. A 
total of 234 different variants was reported, of which five, p.Arg243Gln, c.611>G, 
p.Arg241Cys, c.331C>T (p.Arg111*) and c.1238G>C (p.Arg413Pro), had a frequency of 
>5% accounted for 52.5% of all alleles. Furthermore 679 different genotypes were reported, 
the most frequent being p.[Arg243Gln];[Arg243Gln]. Korea was the only country that, like 
China, had a high rate of cPKU (71%); this was less common in Japan (37%) and Taiwan 
(25%). The p.Arg243Gln, c.611>G, and p.Arg241Cys were detected in Korea, Taiwan, and 
China, each with allele frequencies >5%. The p.Arg111* and p. Arg413Pro variants were 
common in Japan, China and Taiwan, but not Korea. The splice variant c.442-1G>A (IVS4-
1G>A) was much more prevalent in Korea than in other Eastern Asian countries.   
Genotypes with p.Arg243Gln were common in China (40%) and Korea (27%) (Table 3), 
while those with p.Arg241Cys were prevalent in Taiwan (41%), Japan (27%) and China 
(15%) (Table 3). Patients with the splice site variant c.442-1G>A were more common in 
Korea (18%), followed by China (8%) and Japan (7%). The splice variant c.611A>G (Ex6-
96A>G), which masquerades as missense variant p.Tyr204Cys22, was found 19% of patients 
in China, 13 in Taiwan and 12 in Korea (Table 3). 
Africa 
The low number of reports available from Africa were considered not sufficiently 
representative of this world region. Thus, we did not analyze these data.  
Discussion 
The aim of this study was to elucidate the prevalence of PKU and distribution of causative 
PAH variants worldwide and in different countries. We provided a rough estimation of global 
PKU prevalence by calculating the number of affected patients for countries based on the 
provided PKU prevalence and the total population in 201823 and an average prevalence for 
countries not employing newborn screening for PKU. Overall, it appears that there are about 
0.45 million PKU patients worldwide, of whom at least two thirds have PKU that requires 
treatment (most patients had a severe, cPKU phenotype). An improvement in early diagnosis 
via NBS in countries still lacking it should be an urgent priority. With the multiple allelic 
combinations generated by so many mutations, a full description of all genotype/phenotype 
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correlations is impossible in this report. Nevertheless, it is clear that for many allelic 
combinations, often the most common in a region or country, such correlations are possible as 
detailed in the final three sections in the Results along with Table 2 and Figure S4. 
Recognizing these relationships is important for counseling parents now that newborn 
screening predominates diagnosis of this disorder, particularly in instances when treatment 
recommendations are unclear (e.g., due to borderline blood Phe levels). 
 
Although PKU has been found to be most common in European populations,9 its similar 
prevalence in certain Middle Eastern countries (particularly Turkey and Iran) was a 
remarkable finding.24; 25 A possible contributing factor may be the frequency of consanguinity 
in Islamic cultures, especially marriages between first-cousins, which would favor the 
autosomal recessive inheritance of PKU.26 Prevalence and consanguinity was missing for 
many countries, making it more difficult to assess this hypothesis.27  
We identified 758 different (previously reported) PKU variants in this study, emphasizing the 
strong genetic heterogeneity of PKU. Information of about 16,000 genotypes and phenotypes 
from PKU patients enabled a more detailed study of their distribution across different regions 
and countries than previously possible.28; 29 Overall, the severe p.Arg408Trp variant was the 
most common, especially among Eastern European populations, in accordance with previous 
studies.30,31 Furthermore, p.Arg408Trp dominates most Central European populations 
(Poland, Slovakia, Czechia, Austria, or Germany), again supporting previous studies.32-36  
Previous research had suggested that some PKU variants appeared to have been carried by 
migration, e.g. p.Arg408Trp, c.1066-11G>A, c.1315+1G>A or p.Phe299Cys and 
Arg408Gln.28; 37 Our study supports and extends the knowledge on how certain variants 
appear to have spread within Europe and to different regions and countries worldwide. In 
particular, the distribution of PKU variants across Europe was consistent with successive 
waves of historical migration, and Figure 4 summarizes the likely geographical routes of 
transmission of some variants within Europe.  It was previously suggested that the 
concomitant excess of (unaffected) PKU carriers is at least in part the result of over-dominant 
selection (‘‘heterozygous advantage’’).38 
For example, Germany has occupied a ‘crossroads’ location during several migration waves 
throughout history, and displays a broad spectrum of PAH variants, with similarities to some 
other populations, such as northern European countries (Denmark, Sweden and Norway).36 
This implies a genetic connection of these regions, possibly during the Germanic settlement 
of Scandinavia. Norway’s most frequent variant, p.Gly46Ser, was not observed in the German 
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population. Furthermore, the occurrence of c.1066-11G>A in Germany was surprisingly high 
in our analysis, which might be explained by immigration from Turkey. This variant, often 
described as the “Mediterranean mutation”, may be of Italian origin39 and has been found 
mainly in Southern European countries or the Middle-East.40,41 Our study showed that c.1066-
11G>A has the highest AF in Middle Eastern countries. A typical east-west gradient can be 
seen, originating from Western Asia and the Middle East, i.e., from Armenia (48%) via 
Turkey, Iran, Israel to Spain. 
The p.Arg408Trp-associated genotype, the most common variant in people with Slavic roots, 
followed the east-central-southwest European axis, starting from Estonia and Russia, with the 
highest number of severe PKU patients, via Poland, Czechia, Slovakia, Germany, France, and 
Italy, down to Spain. The high prevalence of cPKU in Russia, and the dominance of the 
severe variant, p.Arg408Trp, were striking, given that Russia has a diverse ethnic 
composition, with as many as 160 ethnic groups.42  
Another well-documented axis exists for the p.Tyr414Cys-associated genotype, from 
Northern to Western Europe, i.e. from Sweden, Norway and Denmark via Germany to the 
Netherlands. Some variants, e.g., c.1315+1G>A, seem to have spread within Scandinavian 
countries at high frequency. The same was true for the p.Glu390Gly-associated genotype 
concentrating between Slovenia, Croatia, Serbia and Austria. A trend were evident for very 
mild p.Ala300Ser-associated genotypes, frequent in Turkey and Israel, Italy to Spain. No 
trends for the distribution of p.Val245Ala and p.Ala403Val across Europe could be seen. 
The influence of migration patterns during history can also be seen in the heterogenous 
spectrum of PAH variants in Latin America. These countries were strongly marked by 
immigration of Europeans, especially from Southern Europe, during colonial times.43 An 
example is p.Val388Met, which was especially prevalent in Brazil and Chile, once colonies of 
Portugal and Spain In Argentina variants frequently occurring in Eastern, Central and 
Northern Europe; e.g., as p.Arg408Trp, p.Arg261Gln and c.1066-11G>A were more 
prevalent. In contrast to Brazil or Argentina, the Mexican population has a high proportion of 
indigenous individuals,  which could be a reason for the exceptional high AF of the 
c.60+5G>T splice variant there.44  
The USA has one of the most multi-racial and ethnic populations in the world. The strongest 
ancestral influence is European, mainly from Germany, Ireland, England, Italy and France45, 
which explains a comparable distribution of PKU variants in the USA and Europe.46 African 
Americans have a much lower PKU incidence than Caucasian Americans.47 It would be of 
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interest to follow up this study with regard to the different rates of growth of major ethnic 
groups (Caucasian, African-American, Hispanic, Asian). 
While the overall PKU prevalence in China was 1:15,924, its distribution across the country 
varies significantly with higher rates in the north in comparison to the south.48 In accordance 
with previous reports, p.R234Q accounts for 23% of all variants in China.49 Three additional 
variants p.Arg243Gln, c.611A>G and p.Arg241Cys (AF>5%) were also common in Korea 
and Taiwan, indicating commonalities of migration movements and evolution among those 
nationalities. Prevalent PKU variants for Europe, Middle East, Latin America and the USA 
were uncommon in the Asian populations.  
Despite immense progress in the diagnosis and treatment of PKU in the last decade, there are 
still too many areas of the world without adequate access to this care starting newborn 
screening. In particular, data from Africa, certain Asian and Southern American as well as 
Caribbean countries were missing.   
Preliminary data indicated the great value of large patient databases with genotype and 
phenotype information and the introduction of the APV and GPV for the genotypic phenotype 
prediction.15 This study extends these previous observations with additional information, and 
has confirmed the power of genotyping in prediction of phenotype and BH4 responsiveness in 
PKU, thus offering a powerful tool of personalized medicine for this inherited metabolic 
disease.  
This study also confirms that functionally mild variants (in a compound heterozygous 
constellation), with a substantial residual PAH activity are always dominant over inactive 
severe variants (null alleles) and give rise to a milder phenotype and often potential BH4 
responsiveness. Compared with severe classic PKU variants, milder variants were much rarer 
in number but determined the milder metabolic phenotype. Interestingly, homozygous mild 
variants have a higher APV and thus a milder phenotype when occurring in a compound 
heterozygous state with a null allele15. As a rule, two inactive severe variants are never BH4-
responsive, although anecdotal reports sometimes suggest otherwise.50 
In conclusion, this study provides an overview of the current distribution of the most 
important PAH variants and patients genotypes in various world regions. This information, 
together with the APV value, helps to predict the metabolic phenotype and the possible 
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Figure S4. Heat maps of the distribution (%) of classic PKU (cPKU), mild PKU (mPKU) and 
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Legends to figures 
Figure 1. Prevalence of PKU (all phenotypes) in 64 countries from 6 world regions. For exact 
prevalence numbers see Table S1. 
Figure 2. A: Boxplot (median, 25th-75th percentile, 1.5) of the maximal pretreatment blood 
Phe concentrations for three metabolic phenotypes in 6,369 PKU patients. The circles in the 
cPKU bar represent ordinary high blood Phe concentrations, since cPKU doesn’t have an 
upper Phe limit for its classification; B: Contour plot of two-dimensional densities of 
pretreatment blood Phe concentrations and corresponding genotypic phenotype values (GPV) 
for 6,115 PKU patients;  
Figure 3. A: Boxplot (median, 25th-75th percentile, 1.5) of GPV in 2,246 BH4 non-responder 
and 1,755 responder PKU patients (for 2,114 out of 6,115 patients GVP was not known); B: 
Boxplot (median, 25th-75th percentile, 1.5) of GPV (APVmax) for 11,584 PKU patients with a 
known genotype, but not tested for BH4 responsiveness. Horizontal grey bar: separation area 
between GPVs for predicted BH4 responsiveness (3.8-10) and non-responsiveness (0-3.3). 
Figure 4. The world map with the relative frequency (%) of PKU and the corresponding most 
common variants for classic PKU (cPKU), mild PKU (mPKU) and mild 
hyperphenylalaninemia (MHP). Exact frequencies and additional genotypic phenotype values 
(GPV) for Europe and other world regions are presented in a more granular form in Figure S4. AF: 
allele frequency; APV: allelic phenotype value (cPKU=0-2.6; mPKU=2.7-6.6; MHP=6.7-10). 
The RefSeq accession number for the PAH is ENSG00000171759; GeneBank: 
NM_000277.1. ac.611A>G reported as Ex6-96A>G splice variant. 
Figure 5.  Patterns of common PAH variants possibly associated with migration in Europe. 
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Table 1. Information included in the database 
 
Information provided n (%) 
All patients 16,974 
Complete genotype  




  4,386 (27) 





  9,923 (62) 
  3,521 (22) 
  2,648 (16) 
Genotype and country 15,357 (91) 
Blood Phe levels 
Blood Phe levels and phenotype 
Blood Phe levels and genotype 
  6,371 (38) 
  6,369 (38) 
  6,115 (36) 
Phenotype, genotype and BH4 responsiveness 
- Non-responder 
- Responder 
  5,597 
  3,191 (57) 
  2,316 (43) 
Number of different genotypes 
- Compound heterozygous 
- Homozygous 
  3,659 
  3,446 (94) 
     213 (6) 
cPKU: classic PKU; mPKU: mild PKU; MHP: mild  
hyperphenylalaninemia; BH4: tetrahydrobiopterin 
 26








No. 1 Frequent genotype 
GF  
(%) 
No. 2 Frequent genotype 
GF  
(%) 


















Europe                                 
Austria 59.7 30.2 10.1 p.[Arg408Trp];[Arg408Trp] 7.0 p.[Arg261Gln];[ Arg408Trp] 6.3 c.[1315+1G>A];[1315+1G>A] 5.6 61 p.Arg408Trp 23.4 c.1315+1G>A 11.2 p.Arg261Gln 6.6 
Bulgaria 64.9 27.0 8.1 p.[Arg408Trp];[Arg408Trp] 16.2 p.[Leu48Ser];[Arg408Trp] 8.1 p.[Leu48Ser]:c.[1066-11G>A] 5.4 20 p.Arg408Trp 32.4 p.Arg261Gln 17.6 p.Leu48Ser 9.5 
Croatia 67.7 19.1 13.2 p.[Leu48Ser];[Arg408Trp] 14.3 p.[Glu390Gly];[Arg408Trp6] 8.6 p.[Arg158Gln];[Arg408Trp] 5.7 26 p.Arg408Trp 31.4 p.Leu48Ser 14.3 p.Glu390Gly 7.1 
Czechia 69.9 7.4 22.7 p.[Arg408Trp];[Arg408Trp] 18.2 p.[Arg408Trp];[Ala403Val] 4.0 p.[Arg158Gln];[Arg408Trp] 3.8 92 p.Arg408Trp 41.7 p.Ala403Val 5.3 p.Arg158Gln 4.6 
Denmark 51.3 28.3 20.4 p.[Tyr414Cys]:c.[1315+1G>A] 8.7 c.[1315+1G>A];[1315+1G>A] 7.7 p.[Arg408Trp]:c.[1315+1G>A] 7.7 83 c.1315+1G>A 27.3 p.Arg408Trp 17.6 p.Tyr414Cys 12.1 
Estonia 93.5 2.2 4.3 p.[Arg408Trp];[Arg408Trp] 66.3 p.[Arg408Trp];[Arg261Gln] 5.4 p.[Arg408Trp;[Leu48Ser] 4.3 16 p.Arg408Trp* 82.6 p.Arg261Gln 2.7 c.1315+1G>A 2.2 
France 59.1 22.0 18.9 p.[Glu280Lys];[Glu280Lys] 2.2 p.[G352Valfs*48];[G352Valfs*48] 1.7 p.[Arg261Gln];[Arg261Gln] 1.5 229 c.1066-11G>A 7.4 p.Arg261Gln 6.5 p.Arg408Trp 5.5 
Germany 32.0 44.0 24.0 p.[Arg408Trp];[Arg408Trp] 4.1 p.[Arg408Trp];[Tyr414Cys] 2.7 p.[Arg261Gln];[Arg261Gln] 2.4 102 p.Arg408Trp 19.3 p.Tyr414Cys 9.7 c.1315+1G>A 8.8 
Italy 39.1 24.3 36.6 p.[Arg261Gln]:c.[1066-11G>A] 2.8 c.[1066-11G>A];[1066-11G>A] 2.2 p.[Arg261Gln];[Arg261Gln] 1.8 159 p.Arg261Gln 10.7 c.1066-11G>A 10.6 p.Ala403Val 8.4 
Netherlands 42.0 37.2 20.8 p.[Tyr414Cys]:c.[1315+1G>A] 4.5 p.[Arg261Gln]:c.[1315+1G>A] 3.6 p.[Pro281Leu]:c.[1315+1G>A] 2.7 65 c.1315+1G>A 13.7 p.Arg261Gln* 8.5 p.Pro281Leu 7.6 
Norway 52.1 43.8 4.2 p.[Gly46Ser]:c.[1315+1G>A] 12.2 p.[Gly46Ser]:c.[842+1G>A] 6.1 p.[Gly46Ser];[Phe299Cys] 6.1 24 p.Gly46Ser 16.3 p.Tyr414Cys 13.3 c.1315+1G>A 12.2 
Poland 74.0 10.9 15.1 p.[Arg408Trp];[Arg408Trp] 40.0 p.[Arg408Trp]:c.[1066-11G>A] 5.6 p.[Arg408Trp];[Arg158Gln] 4.4 94 p.Arg408Trp 64.6 c.1066-11G>A 4.3 p.Arg158Gln 3.5 
Portugal 52.9 34.3 12.7 p.[Arg261Gln];[Arg261Gln] 7.8 c.[1066-11G>A];[1066-11G>A] 5.9 p.[Arg261Gln];[Val388Met] 4.9 34 c.1066-11G>A 16.2 p.Arg261Gln 16.2 p.Val388Met 11.3 
Russia 81.0 9.9 9.1 p.[Arg408Trp];[Arg408Trp] 31.6 p.[Arg261Gln];[Arg408Trp] 5.0 p.[Pro281Leu];[Arg408Trp] 3.7 148 p.Arg408Trp 53.7 p.Arg261Gln 5.6 p.Pro281Leu 4.1 
Serbia 48.0 28.0 24.0 p.[Leu48Ser];[Leu48Ser] 14.7 p.[Leu48Ser];[Arg408Trp] 10.7 p.[Leu48Ser];[ Arg158Gln] 4.0 30 p.Leu48Ser 31.3 p.Arg408Trp 14.7 p.Ile306Val 7.3 
Slovakia 72.6 5.9 21.5 p.[Arg408Trp];[Arg408Trp] 26.5 p.[Arg408Trp]:c.[1315+1G>A] 4.6 p.[Arg408Trp];[Ala403Val] 4.6 51 p.Arg408Trp 47.9 p.Arg158Gln 5.9 c.1315+1G>A 5.0 
Slovenia 34.1 22.7 43.2 p.[Arg158Gln];[Glu390Gly] 9.1 p.[Arg261Gln];[Glu390Gly] 9.1 p.[Pro281Leu];[Ala403Val] 6.8 27 p.Arg408Trp 12.5 p.Glu390Gly 11.4 p.Arg158Gln 11.4 
Spain 41.6 28.8 29.6 c.[1066-11G>A];[1066-11G>A] 5.2 p.[Ile65Thr]:c.[1066-11G>A] 2.0 p.[Arg261Gln]:c.[1066-11G>A] 2.0 155 c.1066-11G>A 11.1 p.Val388Met 6.8 p.Ile65Thr 6.4 
Sweden 41.8 43.6 14.6 p.[Arg408Trp]:c.[1315+1G>A] 16.4 p.[Arg408Trp];[Arg408Trp] 10.9 p.[Tyr414Cys]:c.[1315+1G>A] 9.1 12 p.Arg408Trp 27.3 p.Tyr414Cys 23.6 c.1315+1G>A 21.8 
Switzerland 54.8 30.6 14.6 p.[Arg261Gln];[Arg261Gln] 9.7 p.[Ile95del];[Tyr414Cys] 4.8 p.[Leu48Ser];[Leu48Ser] 4.8 39 p.Arg261Gln 15.3 p.Arg408Trp 8.1 c.1066-11G>A 7.3 
Asia 
China 62.1 27.6 10.3 p.[Arg243Gln];[Arg243Gln] 6.1 p.[Arg243Gln]:c.[611A>G]
a 4.6 p.[Arg241Cys];[Arg243Gln] 3.7 234 p.Arg243Gln 23.3 c.611A>Ga 10.2 p.Arg241Cys 8.0 
Japan 34.5 40.0 25.5 p.[Arg413Pro];[Arg241Cys] 9.1 p.[Arg413Pro];[Arg413Pro] 7.3 p.[Tyr414Cys]:c.[1315+1G>A] 7.3 31 p.Arg413Pro 18.2 p.Arg241Cys 16.4 p.Arg111* 7.3 
Korea 71.0 24.7 4.3 p.[Arg241Cys];[Ala259Thr] 4.3 p.[Arg241Cys];[Arg243Gln] 4.3 c.[611A>G];[611A>G]
a 3.2 47 p.Arg243Gln 13.3 c.442-1G>A 10.1 p.Arg241Cys 8.5 
Taiwan 25.4 47.9 26.8 p.[Arg241Cys];[Arg241Cys] 8.5 p.[Arg241Cys]:c.[611A>G]
a 7.0 p.[Ala434Asp];[Arg408Trp] 2.8 34 p.Arg241Cys 24.6 p.Arg408Gln 12.0 c.611A>Ga 7.7 
North America                                 
USA 58.6 27.2 14.2 p.[Arg408Trp];[Arg408Trp] 4.0 c.[1066-11G>A];[1066-11G>A] 3.1 p.[Arg408Gln]:c.[1315+1G>A] 2.5 214 p.Arg408Trp 18.5 c.1066-11G>A 7.8 c.1315+1G>A 6.9 
Latin America 
Argentina 45.4 26.8 27.8 p.[Arg408Trp];[Arg408Trp] 4.1 p.[Arg408Trp];[Ala403Val] 3.1 p.[Val388Met];[Tyr414Cys] 3.1 47 p.Arg408Trp   10.3 p.Arg261Gln  9.8 c.1066-11G>A   9.3 
Brazil 63.0 34.2 2.8 p.[Val388Met];[Val388Met] 5.0 p.[Arg261Gln];[Arg261Gln] 3.7 c.[1066-11G>A];[1066-11G>A] 2.3 56 p.Val388Met 16.2 p.Arg261Gln 11.6 c.1066-11G>A 9.4 
Mexico 56.5 30.4 13.1 c.[60+5G>T];[60+5G>T] 10.6 p.[Val388Met]:c.[60+5G>T] 10.6 c.[60+5G>A];[441+5G>T] 4.3 33 c.60+5G>T 23.4 p.Val388Met 9.6 c.1066-11G>A 7.4 
Middle East 
Iran 81.1 10.3 8.6 c.[1066-11G>A];[1066-11G>A] 18.4 p.[Arg261Gln];[Arg261Gln] 7.6 c.[168+5G>C];[168+5G>C] 6.8 106 c.1066-11G>A 22.1 p.Arg261Gln 9.7 c.168+5G>C 8.7 
Israel 50.5 21.7 27.8 c.[1066-11G>A];[1066-11G>A] 9.4 p.[Leu48Ser];[Leu48Ser] 5.2 c.[168+1G>A];[168+1G>A] 3.8 55 c.1066-11G>A 15.1 p.Leu48Ser 10.8 p.Ala403Val 7.3 
Saudi Arabia 85.0 9.0 6.0 p.[Arg252Trp];[Arg252Trp] 25.4 p.[Val388Met];[Val388Met] 10.4 p.[Arg261*];[Arg261*] 9.0 21 p.Arg252Trp 27.6 p.Arg261* 11.2 p.Val388Met 10.4 
Turkey 42.1 22.7 35.2 c.[1066-11G>A];[1066-11G>A] 13.9 p.[Arg261Gln];[Arg261Gln] 8.3 p.[Pro281Leu];[Pro281Leu] 4.6 64 c.1066-11G>A 22.9 p.Arg261Gln 11.8 p.Leu48Ser 8.8 
Australia 80.4 14.1 5.4 p.[Arg261Gln]:c.[1315+1G>A] 7.4 p.[Arg408Trp]:c.[1315+1G>A] 7.4 c.[1315+1G>A];[1315+1G>A] 6.3 37 c.1315+1G>A 23.2 p.Arg408Trp 20.5 p.Ile65Thr 10.5 
*c.611A>G reported as Ex6-96A>G splice variant. The RefSeq accession number for the PAH is ENSG00000171759; GeneBank: NM_000277.1. 
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Table 3. Frequency (%) of patients with common variants on at least one allele (compound heterozygotes or homozygotes) in  
different countries. Source BIOPKU database. 
 
p.Gly46Ser %** p.Leu48Ser % p.Ile65Thr %** p.Arg158Gln %** p.Arg241Cys %** p.Arg408Trp %** p.Arg261Gln %** 
Norway 32.7 Serbia 48.0 Ireland 45.5 Slovenia 22.7 Taiwan 40.8 Estonia 98.9 Bulgaria 29.7 
Denmark 2.0 Croatia 25.7 Australia 17.9 Italy 10.3 Japan 27.3 Poland 89.2 Portugal 23.5 
Spain 1.8 Bulgaria 18.9 Brazil 12.8 Slovakia 10.0 China 15.0 Romania 87.5 Switzerland 21.0 
Brazil 0.9 Israel 16.5 Spain 12.1 Netherlands 9.9 S. Korea 14.9 Russia 75.7 Brazil 20.5 
USA 0.4 Turkey 13.4 Portugal 10.8 Czechia 8.6 Netherlands 4.5 Slovakia 69.4 Italy 19.7 
        Czechia 64.6 Argentina 17.5 
p.Arg243Gln %** p.Val245Ala % p.Arg252Trp %** p.Glu280Lys %** p.Pro281Leu %** Croatia 57.1 Netherlands 15.7 
China 40.4 Italy 4.9 Saudi Arabia 29.9 France 5.1 Netherlands 14.8 Bulgaria 48.6 Turkey 15.3 
S. Korea 26.6 Slovakia 2.3 Brazil 9.6 USA 4.3 Turkey 11.2 Sweden 43.6 Slovenia 13.6 
USA 19.7 Germany 2.1 Portugal 6.9 Australia 4.2 Portugal 10.8 Austria 39.9 Germany 13.6 
Taiwan 11.3 Denmark 1.5 Slovakia 6.8 Spain 3.5 Italy 10.3 Germany 35.7 Croatia 12.9 
Spain 5.1 France 1.2 Czechia 5.1 Russia 2.5 Germany 9.4 Australia 34.7 Austria 12.6 
        USA 32.9 Spain 11.9 
p.Phe299Cys %** p.Ala300Ser % p.Val388Met %** p.Glu390Gly %** p.Ala403Val %** Denmark 28.8 Iran 11.8 
Norway 14.3 Turkey 13.0 Chile 52.4 Slovenia 22.7 Italy 15.6 Serbia 28.0 Australia 11.6 
Australia 4.2 Israel 9.0 Brazil 28.8 Croatia 14.3 Slovenia 13.6 Slovenia 22.7 France 11.5 
USA 2.3 Italy 7.1 Portugal 20.6 Serbia 10.7 Israel 13.2 Argentina 16.5 Russia 10.3 
France 1.1 Iran 3.8 Mexico 19.1 Turkey 6.5 Argentina 10.3 Switzerland 14.5 Serbia 9.3 
Russia 0.2 Spain 3.7 Spain 13.1 Austria 5.6 Czechia 10.1 France 9.9 Israel 9.0 
        Turkey 8.8 USA 8.6 
p.Tyr414Cys %** c.611A>G* % c.442-1G>A %** c.1066-11G>A %** c.1315+1G>A %** Israel 7.1 Slovakia 6.8 
Sweden 38.2 China 18.7 Korea 18.1 Armenia 47.8 Denmark 46.9 Brazil 6.8 Estonia 5.4 
Norway 24.5 Taiwan 12.7 China 8.0 Turkey 31.9 Sweden 36.4 Italy 5.7 Poland 3.6 
Denmark 22.2 S. Korea 11.7 Japan 7.3 Iran 25.7 Norway 26.0 Netherlands 4.5 Czechia 2.3 
Germany 18.0 France 0.2 Poland 0.4 Israel 20.8 Netherlands 22.4 Spain 4.0 Denmark 2.3 
Netherlands 11.7 Russia 0.1 Russia 0.1 Spain 20.1 Germany 17.4 Iran 1.4 China 1.6 
*c.611G>A reported as Ex6-96A>G splice variant; **Percentage of patients (of a total number of patients) with a variant occurring in a compound heterozygous or 
homozygous constellation. For a total number of patients in each country see Table S6. The RefSeq accession number for the PAH is ENSG00000171759; GeneBank: 
NM_000277.1. 
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